| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/02/2001 | EP1094828A1 Use of neglected target tissue antigens in modulation of immune responses |
| 05/02/2001 | EP1094826A1 Novel therapeutic agents that modulate alpha-1a adrenergic receptors |
| 05/02/2001 | EP1094818A1 Use of tricyclic antidepressants for local analgesia |
| 05/02/2001 | EP1094814A2 Methods and compositions for increasing penetration of hiv protease inhibitors |
| 05/02/2001 | EP1094810A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 05/02/2001 | EP1094806A2 Vasculoprotector |
| 05/02/2001 | EP1094798A2 INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 05/02/2001 | EP1094797A1 Transdermal plaster containing at least one active ingredient which influences blood serum lipid levels |
| 05/02/2001 | EP1094711A1 Methods for eradication of nanobacteria |
| 05/02/2001 | EP1071329A4 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 05/02/2001 | EP0984959A4 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| 05/02/2001 | EP0983257A4 Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| 05/02/2001 | EP0973392A4 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/02/2001 | EP0882010B1 Pharmaceutical agents containing perfluoroalkyl-containing metal complexes and the use thereof in tumour therapy and interventional radiology |
| 05/02/2001 | EP0743853B1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 05/02/2001 | CN1293573A Methods of treating tardive dyskinesia and other movement disorders |
| 05/02/2001 | CN1293565A Compositions for regulating skin appearance |
| 05/02/2001 | CN1293564A Method for regulating skin apperance |
| 05/02/2001 | CN1065140C synergistic therapeutic composition and methods |
| 05/01/2001 | US6225457 Polynucleotide sequences associated with bacterial proteins; for detection of bactericides |
| 05/01/2001 | US6225326 Administering insulin sensitivity enhancer in combination with an .alpha.-glucosidase inhibitor for therapy to reduce side effect for diabetic patient |
| 05/01/2001 | US6225325 Administering n-substituted-1,5-dideoxy-1,5-imino-d-glucitol or galactitol for prophylaxis, therapy, reducing, or reversing multidrug resistance in patient undergoing therapy with chemotherapeutic agent |
| 05/01/2001 | US6225301 Particularly using the isozyme selective pkc inhibitor, (s)-3,4-(n, n'-1,1'-((2?-ethoxy)-3'?(o)-4'?-(n,n-dimethylamino)-butane)-bi s-(3, 3'-indolyl) )-1(h)-pyrrole-2,5-dione hydrochloride salt |
| 05/01/2001 | US6225098 UDP-N-acetylenolpyruvyglucosamine reductase |
| 05/01/2001 | US6225087 Polynucleotide which codes for a polypeptide of defined amino acid sequence; drug screening of bactericides against streptococcus; otitis media; conjunctivitis; pneumonia; meningitis; sinusitis; pleural empyema; endocarditis |
| 05/01/2001 | US6225083 Nucleotide and amino acid sequences of membrane protein involved in cell division; drug screening; bactericides; bacteriostats; antibiotics; for meningitis, sinusitis, conjunctivitis, otitis media, and endocarditis |
| 05/01/2001 | US6225057 Duplications of human chromosome 15q24-25 and anxiety disorders, diagnostic methods for their detection |
| 05/01/2001 | US6224912 Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
| 05/01/2001 | US6224909 Fast decomposing pellets |
| 05/01/2001 | US6224907 Anti-asthma therapy |
| 05/01/2001 | US6224891 Compounds and methods for the treatment of bacterial dysentery using antibiotics and toxin binding oligosaccharide compositions |
| 05/01/2001 | US6224887 Antifungal nail lacquer and method using same |
| 05/01/2001 | US6224869 Isolated polypeptide |
| 05/01/2001 | US6224865 Suppression of inhibitors |
| 05/01/2001 | US6224862 Mixture of prothrombinase and protein; anticoagulant |
| 04/29/2001 | CA2325069A1 Use of corticotropin releasing factor antagonists and related compositions |
| 04/27/2001 | CA2324538A1 Gastric acid secretion |
| 04/26/2001 | WO2001029563A1 Method of screening for inhibitors of asp2 |
| 04/26/2001 | WO2001029256A2 Cephalic pain susceptibility marker |
| 04/26/2001 | WO2001029255A2 Diagnostic test for cephalic pain |
| 04/26/2001 | WO2001029219A1 Human cub-domain-containing protein and gene encoding the same |
| 04/26/2001 | WO2001029199A1 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 04/26/2001 | WO2001029178A2 Epo primary response gene 1, eprg1 |
| 04/26/2001 | WO2001029129A1 Highly-neutralized ethylene copolymers and their use in golf balls |
| 04/26/2001 | WO2001029082A1 A DNA MOLECULE ENCODING A VARIANT α2B-ADRENOCEPTOR PROTEIN, AND USES THEREOF |
| 04/26/2001 | WO2001029073A1 Methods for improving secondary metabolite production in fungi |
| 04/26/2001 | WO2001029071A2 Genes associated with obesity and methods for using the same |
| 04/26/2001 | WO2001029061A1 Novel fusidic acid derivatives |
| 04/26/2001 | WO2001029056A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 04/26/2001 | WO2001029054A2 Medicaments for treatment of respiratory syncytial virus infections |
| 04/26/2001 | WO2001029037A2 Condensed naphthyridines as hiv reverse transcriptase inhibitors |
| 04/26/2001 | WO2001029036A2 Allosteric sites on muscarinic receptors |
| 04/26/2001 | WO2001029025A2 Tyrosine kinase inhibitors |
| 04/26/2001 | WO2001028993A2 Tyrosine kinase inhibitors |
| 04/26/2001 | WO2001028594A2 Tumor detection by imaging and therapy of tumors |
| 04/26/2001 | WO2001028591A2 Injection vehicle for polymer-based formulations |
| 04/26/2001 | WO2001028589A2 Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase |
| 04/26/2001 | WO2001028587A2 Magnetic targeted carrier |
| 04/26/2001 | WO2001028580A2 Modulation of angiogenesis |
| 04/26/2001 | WO2001028579A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 04/26/2001 | WO2001028578A2 A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME |
| 04/26/2001 | WO2001028548A1 Treatment of heart disease with cox-2 inhibitors |
| 04/26/2001 | WO2001028545A2 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 04/26/2001 | WO2001028543A1 TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY |
| 04/26/2001 | WO2001028542A2 Combination therapy including camptothecin |
| 04/26/2001 | WO2001028533A2 PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA |
| 04/26/2001 | WO2001028515A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 04/26/2001 | WO2001028509A1 Depilatories and agents for external use |
| 04/26/2001 | WO2001028472A1 Drug delivery device |
| 04/26/2001 | WO2001028356A2 Food supplement for increasing lean mass and strength |
| 04/26/2001 | WO2001028321A1 Diabetes onset model mammal |
| 04/26/2001 | WO2001006990A3 Use of etodolac to treat cancer |
| 04/26/2001 | WO2001005970A3 Gtp-binding protein associated factors |
| 04/26/2001 | WO2001003645A3 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 04/26/2001 | WO2000077040A3 Human intracellular signaling molecules |
| 04/26/2001 | WO2000075121A3 Process for preparing 10,11-methanobenzosuberane derivatives |
| 04/26/2001 | WO2000071153A3 Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors |
| 04/26/2001 | WO2000061151A3 Oligodeoxynucleotide and its use to induce an immune response |
| 04/26/2001 | WO2000059447A3 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
| 04/26/2001 | WO2000057869A3 Viral treatment |
| 04/26/2001 | WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/26/2001 | WO2000055125A3 N-cyanomethyl amides as protease inhibitors |
| 04/26/2001 | CA2388450A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 04/26/2001 | CA2388427A1 Methods for improving secondary metabolite production in fungi |
| 04/26/2001 | CA2388421A1 Human cub-domain-containing protein and gene encoding the same |
| 04/26/2001 | CA2387962A1 A dna molecule encoding a variant .alpha.2b-adrenoceptor protein, and uses thereof |
| 04/26/2001 | CA2387928A1 Genes associated with obesity and methods for using the same |
| 04/26/2001 | CA2387925A1 Magnetic targeted carrier composed of iron and porous materials for the targeted delivery of biologically active agents |
| 04/26/2001 | CA2387919A1 Methods and compositions for predicting, diagnosing and treating lipodystrophy |
| 04/26/2001 | CA2387896A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors |
| 04/26/2001 | CA2387840A1 Tyrosine kinase inhibitors |
| 04/26/2001 | CA2387786A1 Treatment of eosinophil associated pathologies by modulating pkc-.delta. activity |
| 04/26/2001 | CA2386422A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 04/26/2001 | CA2386149A1 Allosteric sites on muscarinic receptors |
| 04/26/2001 | CA2385958A1 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 04/26/2001 | CA2384573A1 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 04/26/2001 | CA2384537A1 Modulation of angiogenesis |
| 04/25/2001 | EP1094317A1 Method to identify compounds which modulate FRA-1 expression |
| 04/25/2001 | EP1094109A2 Human G protein-coupled receptor, PFI-010 |
| 04/25/2001 | EP1094076A1 Human G-protein coupled receptor |